Proton pump inhibitor use and enteric infections

American Journal of Gastroenterology

Volumn 104, Issue SUPPL. 2, 2009, Pages

  Dial, M Sandra ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

CAMPYLOBACTER; CHOLERA; CLOSTRIDIUM DIFFICILE; DIARRHEA; DISEASE ASSOCIATION; DRUG SURVEILLANCE PROGRAM; ESCHERICHIA COLI; GASTROENTERITIS; GASTROESOPHAGEAL REFLUX; GIARDIA; GIARDIASIS; HUMAN; INFECTIOUS DIARRHEA; INTESTINE INFECTION; LISTERIA; LISTERIOSIS; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SALMONELLA; SALMONELLOSIS; SHIGELLA; SHIGELLOSIS; STRONGYLOIDES; TRAVELLER DIARRHEA; VIRUS INFECTION;

ANTI-ULCER AGENTS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; INFECTION; PROTON PUMP INHIBITORS;

EID: 61949147274     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.46     Document Type: Review

References (94)

1. McNabb PC, Tomasi TB. Host defense mechanisms at mucosal surfaces. Annu Rev Microbiol 1981;35:477-96.
2. Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol 1977;31:107-33.
3. Howden CW, Hunt RH. Relationship between gastric secretion and infection. Gut 1987;28:96-107.
4. Tennant SM, Hartland EL, Phumoonna T et al. Influence of gastric acid on susceptibility to infection with ingested bacterial pathogens. Infect Immun 2008;76:639-45.
5. Parkman HP, Urbain JL, Knight LC et al. Effect of gastric acid suppressants on human gastric motility. Gut 1998;42:243-50.
6. Dinsmore JE, Jackson RJ, Smith SD. The protective role of gastric acidity in neonatal bacterial translocation. J Pediatr Surg 1997;32:1014-6.
7. Goddard AF, Spiller RC. The effect of omeprazole on gastric juice viscosity, pH and bacterial counts. Aliment Pharmacol Ther 1996;10:105-9.
8. Lewis SJ, Franco S, Young G et al. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther 1996;10:557-61.
9. Williams C, McColl KE. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther 2006;23:3-10.
10. Yoshida N, Yoshikawa T, Tanaka Y et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors - inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther 2000;14(Suppl 1):74-81.
11. Zedtwitz-Liebenstein K, Wenisch C et al. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med 2002;30:1118-22.
12. Agastya G, West BC, Callahan JM. Omeprazole inhibits phagocytosis and acidification of phagolysosomes of normal human neutrophils in vitro. Immunopharmacol Immunotoxicol 2000;22:357-72.
13. Bartle H, Harkins M. The gastric secretion: its bactericidal value to man. Amer J Med Sci 1925;169:373-88.
14. Hurst AF. The clinical importance of achlorhydria. Brit Med J 1934;2:665-9.
15. Martinsen TC, Bergh K, Waldum HL. Gastric juice: a barrier against infectious diseases. Basic Clin Pharmacol Toxicol 2005;96:94-102.
16. Claessens AA, Heerdink ER, van Eijk JT et al. Characteristics of diarrhoea in 10,008 users of lansoprazole in daily practice: which co-factors contribute? Pharmacoepidemiol Drug Saf 2002;11:703-8.
17. Leufkens H, Claessens A, Heerdink E et al. A prospective follow-up study of 5669 users of lansoprazole in daily practice. Aliment Pharmacol Ther 1997;11:887-97.
18. Martin RM, Dunn NR, Freemantle S et al. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br J Clin Pharmacol 2000;50:366-72.
19. Wilton LV, Key C, Shakir SA. The pharmacovigilance of pantoprazole: the results of postmarketing surveillance on 11 541 patients in England. Drug Saf 2003;62:121-32.
20. Maton PN, Vakil NB, Levine JG et al. Safety and efficacy of long-term esomeprazole therapy in patients with healed erosive oesophagitis. Drug Saf 2001;24:625-35.
21. Bardhan KD, Bishop AE, Polak JM et al. Pantoprazole in severe acid-peptic disease: the effectiveness and safety of 5 years' continuous treatment. Dig Liver Dis 2005;37:10-22.
22. Hauben M, Horn S, Reich L et al. Association between gastric acid suppressants and Clostridium difficile colitis and community-acquired pneumonia: analysis using pharmacovigilance tools. Int J Infect Dis 2007;11:417-22.
23. Pilotto A, Franceschi M, Vitale D et al. The prevalence of diarrhea and its association with drug use in elderly outpatients: a multicenter study. Am J Gastroenterol 2008;103:2816-23.
24. Al Abri SS, Beeching NJ, Nye FJ. Traveller's diarrhoea. Lancet Infect Dis 2005;5:349-60.
25. Van De WK, Van den DA, Van Gompel A et al. Factors influencing standard pretravel health advice - a study in Belgium. J Travel Med 2007;14:288-96.
26. DuPont HL. Travellers' diarrhoea: contemporary approaches to therapy and prevention. Drugs 2006;66:303-14.
27. Cobelens FG, Leentvaar-Kuijpers A, Kleijnen J et al. Incidence and risk factors of diarrhoea in Dutch travellers: consequences for priorities in pre-travel health advice. Trop Med Int Health 1998;3:896-903.
28. Giannella RA, Broitman SA, Zamcheck N. Gastric acid barrier to ingested microorganisms in man: studies in vivo and in vitro. Gut 1972;13:251-6.
29. Goldberg M. Enteric Infections due to Campylobacter, Salmonella, Shigella, Yersinia, Vibrio, and Helicobacter. Dale D. ACP Medicine (7. IX), pp 1-14. Accessed on 20 August 2006. 14 December 2007.
30. KUNZ LJ, WADDELL WR. Association of Salmonella enteritis with operations on the stomach. N Engl J Med 1956;255:555-9.
31. Doorduyn Y, Van Den Brandhof WE, Van Duynhoven YT et al. Risk factors for Salmonella Enteritidis and Typhimurium (DT104 and non-DT104) infections in The Netherlands: predominant roles for raw eggs in Enteritidis and sandboxes in Typhimurium infections. Epidemiol Infect 2006;134:617-26.
32. Doorduyn Y, Van Pelt W, Siezen CL et al. Novel insight in the association between salmonellosis or campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases. Epidemiol Infect 2008;136:1225-34.
33. Garcia Rodriguez LA, Ruigomez A, Panes J. Use of Acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol 2007;5:1418-23.
34. Garcia Rodriguez LA, Ruigomez A. Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk? Epidemiology 1997;8:571-4.
35. Neal KR, Briji SO, Slack RC et al. Recent treatment with H2 antagonists and antibiotics and gastric surgery as risk factors for Salmonella infection. BMJ 1994;308:176.
36. Wingate DL. Acid reduction and recurrent enteritis. Lancet 1990;335:222.
37. Neal KR, Scott HM, Slack RC et al. Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study. BMJ 1996;312:414-5.
38. Neal KR, Slack RC. Diabetes mellitus, anti-secretory drugs and other risk factors for campylobacter gastroenteritis in adults: a case-control study. Epidemiol Infect 1997;119:307-11.
39. Nalin DR, Levine RJ, Levine MM et al. Cholera, non-vibrio cholera, and stomach acid. Lancet 1978;2:856-9.
40. Evans CA, Gilman RH, Rabbani GH et al. Gastric acid secretion and enteric infection in Bangladesh. Trans R Soc Trop Med Hyg 1997;91:681-5.
41. Forssman B, Mannes T, Musto J et al. Vibrio cholerae O1 El Tor cluster in Sydney linked to imported whitebait. Med J Aust 2007;187:345-7.
42. Ho JL, Shands KN, Friedland G et al. An outbreak of type 4b Listeria monocytogenes infection involving patients from eight Boston hospitals. Arch Intern Med 1986;146:520-4.
43. Czuprynski CJ, Faith NG. Sodium bicarbonate enhances the severity of infection in neutropenic mice orally inoculated with Listeria monocytogenes EGD. Clin Diagn Lab Immunol 2002;9:477-81.
44. Cook GC. Infective gastroenteritis and its relationship to reduced gastric acidity. Scand J Gastroenterol Suppl 1985;111:17-23.
45. Larner AJ, Hamilton MI. Review article: infective complications of therapeutic gastric acid inhibition. Aliment Pharmacol Ther 1994;8:579-84.
46. Haas J, Bucken EW. On the pathogenicity of the lamblia infections. Dtsch Med Wochenschr 1967;92:1869-71.
47. Khatami SS, Mukunda B, Ravakhah K. Coinfection with Giardia lamblia and Clostridium difficile after use of ranitidine. Am J Med Sci 2004;327:91-3.
48. Rousseau MC, Catala A, Blaya J. Association between pulmonary and digestive infections in patients receiving gastric acid-lowering medications for a long duration. Brain Inj 2003;17:883-7.
49. Gurian L, Ward TT, Katon RM. Possible foodborne transmission in a case of pseudomembranous colitis due to Clostridium difficile: influence of gastrointestinal secretions on Clostridium difficile infection. Gastroenterology 1982;83:465-9.
50. Jump RL, Pultz MJ, Donskey CJ. Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea? Antimicrob Agents Chemother 2007;51:2883-7.
51. Buggy BP, Wilson KH, Fekety R. Comparison of methods for recovery of Clostridium difficile from an environmental surface. J Clin Microbiol 1983;18:348-52.
52. Wilson KH, Sheagren JN, Freter R. Population dynamics of ingested Clostridium difficile in the gastrointestinal tract of the Syrian haster. J Infect Dis 1985;151:355-61.
53. Wilson KH. Efficiency of various bile salt preparations for stimulation of Clostridium difficile spore germination. J Clin Microbiol 1983;18:1017-9.
54. Theisen J, Nehra D, Citron D et al. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg 2000;4:50-4.
55. Thorens J, Froehlich F, Schwizer W et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996;39:54-9.
56. Kaur S, Vaishnavi C, Prasad KK et al. Comparative role of antibiotic and proton pump inhibitor in experimental Clostridium difficile infection in mice. Microbiol Immunol 2007;51:1209-14.
57. Paredes-Sabja D, Bond C, Carman RJ et al. Germination of spores of Clostridium difficile strains, including isolates from a hospital outbreak of Clostridium difficile-associated disease (CDAD). Microbiology 2008;154:2241-50.
58. Dial S, Delaney JA, Barkun AN et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005;294:2989-95.
59. Dial S, Delaney JA, Schneider V e t al. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ 2006;175:745-8.
60. Lowe DO, Mamdani MM, Kopp A et al. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin Infect Dis 2006;43:1272-6.
61. Wilcox MH, Mooney L, Bendall R et al. A case-control study of community-associated Clostridium difficile infection. J Antimicrob Chemother 2008;26:388-96.
62. Dial S, Kezouh A, Dascal A et al. Patterns of antibiotic use and risk of hospital admission for Clostridium difficile infection among elderly people in Quebec. CMAJ 2008;179:767-72.
63. Dubberke E, Reske K, Yan Y et al. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis 2007;45:1543-9.
64. Morley JE. The aging gut: physiology. Clin Geriatr Med 2007;23:757-7vi.
65. Cunningham R, Dale B, Undy B et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003;45:243-5.
66. Dial S, Alrasadi K, Manoukian C et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004;171:33-8.
67. Yip C, Loeb M, Salama S et al. Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea. Infect Control Hosp Epidemiol 2001;22:572-5.
68. Modena S, Bearelly D, Swartz K et al. Clostridium difficile among hospitalized patients receiving antibiotics: a case-control study. Infect Control Hosp Epidemiol 2005;26:685-90.
69. Muto CA, Pokrywka M, Shutt K et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273-80.
70. Al Tureihi FI, Hassoun A, Wolf-Klein G et al. Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients. J Am Med Dir Assoc 2005;6:105-8.
71. Baxter R, Ray GT, Fireman B. Case Control Study of Antibiotic Use and Subsequent Clostridium difficile Associated Diarrhea in Hospitalized Patients. Infect Control Hosp Epidemiol 2008;29:44-50.
72. Kyne L, Warny M, Qamar A et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000;342:390-7.
73. Gerding DN, Olson MM, Peterson LR et al. Clostridium difficile-associated diarrhea and colitis in adults - a prospective case-controlled epidemiologic study. Arch Intern Med 1986;416:95-100.
74. Brown E, Talbot GH, Axelrod P et al. Risk factors for Clostridium difficile toxin-associated diarrhea. Infect Control Hosp Epidemiol 1990;11:283-90.
75. Kazakova SV, Ware K, Baughman B et al. A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Arch Intern Med 2006;166:2518-24.
76. Yearsley KA, Gilby LJ, Ramadas AV et al. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. Aliment Pharmacol Ther 2006;24:613-9.
77. Kyne L, Sougioultzis S, McFarland LV et al. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol 2002;23:653-9.
78. Asha NJ, Tompkins D, Wilcox MH. Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus. J Clin Microbiol 2006;44:2785-91.
79. Akhtar AJ, Shaheen M. Increasing incidence of Clostridium difficile-associated diarrhea in African-American and Hispanic patients: association with the use of proton pump inhibitor therapy. J Natl Med Assoc 2007;99:500-4.
80. Aseeri M, Schroeder T, Kramer J et al. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol 2008;103:2308-13.
81. Shah S, Lewis A, Leopold D et al. Gastric acid suppression does not promote clostridial diarrhoea in the elderly. QJM 2000;93:175-81.
82. Loo VG, Poirier L, Miller MA et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-9.
83. McFarland LV, Clarridge JE, Beneda HW et al. Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a veterans administration health care system. Clin Infect Dis 2007;45:1141-51.
84. Beaulieu M, Williamson D, Pichette G et al. Risk of Clostridium difficile-associated disease among patients receiving proton pump inhibitors in a Quebec medical intensive care unit. Infect Control Hosp Epidemiol 2007;28:1305-7.
85. Pepin J, Saheb N, Coulombe MA et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254-60.
86. Dubberke ER, Reske KA, Olsen MA et al. Evaluation of Clostridium difficile-associated disease pressure as a risk factor for C. difficile-associated disease. Arch Intern Med 2007;167:1092-7.
87. Canani RB, Cirillo P, Roggero P et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006;117:e817-20.
88. Laheij R, Sturkenboom MC, Hassing R et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004;292:1955-60.
89. Gulmez SE, Holm A, Frederiksen H et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007;167:950-5.
90. Campbell M, Obstein K, Reddy K et al. Association between proton pump inhibitor use and spontaneous bacterial peritonitis. Dig Dis Sci 0208;53:394-8.
91. McNeil S, Malani P, Chenoweth C et al. Vancomycin resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin Infect Dis 2006;42:195-203.
92. Pasqualotto AC, Nedel WL, Machado TS et al. A comparative study of risk factors and outcome among outpatient-acquired and nosocomial candidaemia. J Hosp Infect 2005;60:129-34.
93. Clabots CR, Johnson S, Olson MM et al. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis 1992;166:561-7.
94. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007;102:2047-56.